Compare BLFS & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLFS | AMPH |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2013 | 2005 |
| Metric | BLFS | AMPH |
|---|---|---|
| Price | $22.46 | $27.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $31.00 |
| AVG Volume (30 Days) | ★ 344.0K | 307.3K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.05 | 17.69 |
| EPS | N/A | ★ 1.52 |
| Revenue | $82,254,000.00 | ★ $731,967,000.00 |
| Revenue This Year | $18.45 | $1.31 |
| Revenue Next Year | $16.27 | $4.85 |
| P/E Ratio | ★ N/A | $18.40 |
| Revenue Growth | N/A | ★ 13.59 |
| 52 Week Low | $19.15 | $20.39 |
| 52 Week High | $29.57 | $31.26 |
| Indicator | BLFS | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 46.50 |
| Support Level | $20.34 | $26.90 |
| Resistance Level | $23.00 | $27.56 |
| Average True Range (ATR) | 0.86 | 0.90 |
| MACD | 0.10 | -0.14 |
| Stochastic Oscillator | 47.23 | 15.43 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.